Low molecular weight heparin (dalteparin) for the treatment of venous thromboembolism in pregnancy

• DOI: 10.1046/j.1471-0528.2003.02182.x
• Publication Date: 2003-12-22T12:51:18Z
• Authors: Anne Flem Jacobsen; Erik Qvigstad; Per Morten Sandset
• Keywords: Adult; Dalteparin; Norway; Pregnancy Complications, Cardiovascular; Pregnancy Outcome; Anticoagulants; 3. Good health; 03 medical and health sciences; Treatment Outcome; 0302 clinical medicine; Pregnancy; Thromboembolism; Acute Disease; Factor Xa; Humans; Female

Objective To evaluate the effect and dose of dalteparin given to pregnant women with acute venous thromboembolism. Design An observational study in Norway. Setting Delivery haematological departments Population Twenty women, aged 22–41 years, thromboembolism verified by objective means. Methods Patients were treated from diagnosis until delivery. Treatment was monitored anti‐activated factor Xa (anti‐Xa) activity, adjusted achieve target 0.5–1.0 U/mL 2–3 hours post‐injection. Main outcome measure Anti‐Xa activity side effects. Result None patients suffered recurrent or major bleeding complications. In 9 13 starting conventional (100 iu/kg bd), escalation necessary reach anti‐Xa activity. six who started 105–118 bd required escalation. One woman 133 reduction. Bioaccumulation not observed. Conclusion Our suggests that may be used for treatment pregnancy. Approximately 10–20% higher doses needed as compared non‐pregnant individuals.